Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Kita-15 Nishi-7, Sapporo, 060-0815, Japan.
Central Institute for Experimental Animals, 3-25-12 Tonomachi, Kawasaki, Kanagawa, 21-0821, Japan.
Sci Rep. 2020 Jul 28;10(1):12625. doi: 10.1038/s41598-020-69690-9.
Recent progress in regenerative medicine has enabled the utilization of pluripotent stem cells (PSCs) as the resource of therapeutic cells/tissue. However, immune suppression is still needed when the donor-recipient combination is allogeneic. We have reported previously that mouse PSCs-derived immunosuppressive cells contribute to prolonged survival of grafts derived from the same mouse PSCs in allogeneic recipients. For its clinical application, a preclinical study using non-human primates such as common marmoset must be performed. In this study, we established the induction protocol of immunosuppressive cells from common marmoset ES cells. Although similar immunosuppressive macrophages could not be induced by same protocol as that for mouse PSCs, we employed an inhibitor for histone methyltransferase, DZNep, and succeeded to induce them. The DZNep-treated macrophage-like cells expressed several immunosuppressive molecules and significantly inhibited allogeneic mixed lymphocyte reaction. The immunosuppressive cells from non-human primate ESCs will help to establish an immunoregulating strategy in regenerative medicine using PSCs.
再生医学的最新进展使得多能干细胞(PSCs)能够被用作治疗细胞/组织的资源。然而,当供体-受体组合为同种异体时,仍然需要免疫抑制。我们之前曾报道过,鼠 PSCs 衍生的免疫抑制细胞有助于同种异体受体中来自同一鼠 PSCs 的移植物的长期存活。为了将其应用于临床,必须在非人类灵长类动物(如普通狨猴)中进行临床前研究。在这项研究中,我们建立了从普通狨猴胚胎干细胞诱导免疫抑制细胞的诱导方案。尽管不能通过与诱导鼠 PSCs 相同的方案来诱导类似的免疫抑制巨噬细胞,但我们使用了组蛋白甲基转移酶抑制剂 DZNep,并成功地诱导了它们。用 DZNep 处理的类巨噬细胞样细胞表达了几种免疫抑制分子,并显著抑制了同种异体混合淋巴细胞反应。来自非人类灵长类动物 ESC 的免疫抑制细胞将有助于建立使用 PSCs 的再生医学中的免疫调节策略。